RxDoctor Payments Data

Adeniyi Babalola, MD

Internal Medicine · Atlanta, GANPI 1497793970

Payments from drug & device makers

$259in general payments, 2019–2025

Across 14 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$53
  • Lilly USA, LLC$38
  • Novo Nordisk$23
  • Shield Therapeutics Inc$22
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$21
  • AstraZeneca$20
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$259 in reported general payments places this provider in the 45th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$5,814
Medicare patients
31
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide29$63,046
MounjaroTirzepatide32$46,916
OzempicSemaglutide22$35,234
JanuviaSitagliptin Phosphate23$30,964
JardianceEmpagliflozin14$17,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,847
Metformin Hcl201$11,979
XareltoRivaroxaban11$11,515
Albuterol Sulfate HfaAlbuterol Sulfate125$3,827
Atorvastatin Calcium270$3,103
SymbicortBudesonide/Formoterol Fumarate12$2,904
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,802
Amlodipine Besylate267$1,748
Rosuvastatin Calcium118$1,290
Omeprazole102$1,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$38$109,96261 claims
Novo NordiskOzempic$23$35,23422 claims
Boehringer IngelheimJardiance$14$17,77714 claims
GSKTrelegy Ellipta$18$12,84718 claims
AstraZenecaSymbicort$20$2,90412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →